EfficacyofTafamidisinPatientsWithHereditaryandWild-TypeTransthyretinAmyloidCardiomyopathy:FurtherAnalysesFromATTR-ACTJACC:HeartFailureOriginalResearchEarlyRecent,Feb01,./j.jchf..09.本文由“天纳”临床学术信息人工智能系统自动翻译点击文末“阅读原文”下载本文PDFCentralIllustrationObjectivesTafamidisisaneffectivetreatmentfortransthyretinamyloidcardiomyopathy(ATTR-CM),thisstudyaimedtodeterminewhetherthereisadifferentialeffectbetweenvarianttransthyretinamyloidosis(ATTRv)andwild-typetransthyretin(ATTRwt).Tafamidis是治疗转甲状腺素淀粉样心肌病（ATTR-CM）的有效药物，本研究旨在探讨变异型转甲状腺素淀粉样变性（ATTRv）与野生型转甲状腺素（ATTRwt）之间是否存在差异。BackgroundATTR-CMisaprogressive,fataldisorderresultingfrommutationsintheATTRvorthedepositionofdenaturedATTRwt.ATTR-CM是一种进行性的致命疾病，由ATRV突变或变性ATRWT沉积引起。MethodsInpre-specifiedanalysesfromATTR-ACT(TafamidisinTransthyretinCardiomyopathyClinicalTrial),baselinecharacteristics,all-causemortality,andchangefrombaselinetomonth30in6-minwalktestdistanceandKansasCityCardiomyopathyQuestionnaireOverallSummaryscorewere
转载请注明：http://www.galanzweibolu.com/rhzlxjb/6541.html
